

**TOMAS NEILAN, MD, MPH**Director, Cardio Oncology
Co-Director, Cardiac MR PET CT Program
Massachusetts General Hospital
Associate Professor of Medicine, Harvard Medical School*will present***“Acute and Chronic Cardiac and Vascular Effects of Contemporary Immune Therapies for Cancer”****Monday, December 5, 2022**

5:30 pm – 6:30 pm EST

Join via Zoom:<https://rutgers.zoom.us/j/96023345627>**Meeting ID: 960 2334 5627****Password: 172916**

To join by Phone

+1 646 558 8656 (US)

Learning Objectives

At the conclusion of this activity, participants should be better able to:

1. Understand the expanding role of immune checkpoint inhibitors in cancer care
2. Understand the acute cardiac toxicities of immune checkpoint inhibitors
3. Understand the sub-acute and chronic cardiac toxicities of immune checkpoint inhibitors and their insight into cardiovascular biology

Target Audience:

This activity is designed for cardiologists, cardiovascular surgeons, internists, family practitioners, researchers, nurses, nurse practitioners, physician assistants, and other health care professionals who care for patients with cardiovascular disease.

**Accreditation:** In support of improving patient care, Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.**Physicians:** Rutgers Biomedical and Health Sciences designates this live activity for a maximum of 1 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.**Nurses:** This activity is awarded 1 contact hours. (60-minute CH)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure Declarations: Dr. Neilan has the following relevant financial relationships with ineligible companies: Grant/Research Support – AstraZeneca, Bristol Myers Squibb; Consultant - AbbVie, Amgen, Bristol Myers Squibb, C-4

Therapeutics, CRO Oncology, Genentech, Intrinsic Imaging, Roche, Sanofi. All of the relevant financial relationships listed have been mitigated. Speakers are required to disclose discussion of off-label/investigational uses of commercial products/devices in their presentation. These disclosures will be made to the audience at the time of the activity.

Planning Committee: Dr. Theodore Maglione (Content Reviewer) has the following relevant financial relationship: Consultant: Medtronic. All of the relevant financial relationships listed have been mitigated. Drs. Partho Sengupta (Activity Director), Deepa Iyer, Amna Zafar, Danyaal Moin, Naveena Yanamala, Grace Casalang-Verzosa, and Lisa Fletcher, RN (Content Reviewers), Purvi Patel and Andrea Bernard have no relevant financial relationships with ineligible companies to disclose.